Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

Next Previous
X
Search
Trial Profile

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aglatimagene besadenovec (Primary) ; Antineoplastics; Atezolizumab; Durvalumab; Nivolumab; Pembrolizumab; Valaciclovir
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Advantagene; Candel Therapeutics

    • Most Recent Events

    • 14 Nov 2024 According to a Candel Therapeutics media release, the company expects to present updated overall survival data from this trial in Q1 2025.
    • 04 Jun 2024 Results (n=73; as of 16 Jan 2024) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 20 May 2024 According to a Candel Therapeutics media release, today announced it will be hosting a webcasted R&D breakfast panel featuring prominent scientific and medical thought leaders to discuss topline overall survival data from its phase 2 clinical trial of CAN-2409. The event will be held on Monday, June 3, 2024, at 7:00 AM Central Time, during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top